360 High-Risk Vulnerability Immunization Tool V2.0 vs Monarx: Side-by-Side Comparison (2026)

360 High-Risk Vulnerability Immunization Tool V2.0: Tool that immunizes Windows systems against critical vulnerabilities. built by 360 Security Group (Qihoo 360). Core capabilities include Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation..

Monarx: Web hosting security platform for threat detection, removal, and protection. built by Monarx. Core capabilities include Threat detection using advanced obfuscation analysis, Automated threat removal with low false positive rate, Real-time runtime application protection (Threat Shield)..

Both serve the Endpoint Protection Platform market but differ in approach, feature depth, and target audience.

360 High-Risk Vulnerability Immunization Tool V2.0 differentiates with Remote desktop vulnerability immunization (CVE-2019-0708, CVE-2019-1181, CVE-2019-1182), MS17-010 SMB vulnerability protection against ransomware, Meltdown CPU vulnerability mitigation. Monarx differentiates with Threat detection using advanced obfuscation analysis, Automated threat removal with low false positive rate, Real-time runtime application protection (Threat Shield).

360 High-Risk Vulnerability Immunization Tool V2.0 is developed by 360 Security Group (Qihoo 360). Monarx is developed by Monarx. The vendor behind a product decides its roadmap, support, and longevity, so check each company's profile before you commit.

360 High-Risk Vulnerability Immunization Tool V2.0 and Monarx serve similar Endpoint Protection Platform use cases. Review the feature comparison above to determine which fits your requirements.